Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
暂无分享,去创建一个
V. Salomaa | T. Jørgensen | R. Schnabel | S. Blankenberg | C. Meisinger | P. Jousilahti | W. Koenig | B. Thorand | P. Brambilla | S. Costanzo | S. Giampaoli | L. Iacoviello | K. Kuulasmaa | A. Linneberg | L. Palmieri | G. Veronesi | F. Kee | M. Ferrario | J. Kontto | U. Landmesser | T. Zeller | J. Yarnell | T. Niiranen | S. Signorini | C. Waldeyer | F. Ojeda | F. Brunner | N. Makarova
[1] A. Hoes,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.
[2] S. Crooke,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.
[3] M. Pirinen,et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA , 2016, Nature Communications.
[4] J. Witztum,et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.
[5] D. Horstkotte,et al. Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation , 2015, Clinical Research in Cardiology Supplements.
[6] Frank Kee,et al. BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries , 2014, European Journal of Epidemiology.
[7] F. Kronenberg,et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. , 2014, Journal of the American College of Cardiology.
[8] M. Pencina,et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. , 2014, Annals of Internal Medicine.
[9] Shah Ebrahim,et al. [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[10] J. Polanin,et al. Combining individual participant and aggregated data in a meta‐analysis with correlational studies , 2012, Research synthesis methods.
[11] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[12] J. Gallacher,et al. Lipid-related markers and cardiovascular disease prediction. , 2012, JAMA.
[13] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[14] M. Taskinen,et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.
[15] J. Borén,et al. Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.
[16] C. Ballantyne,et al. Management of Lp(a). , 2010, Journal of clinical lipidology.
[17] Stephen Kaptoge,et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.
[18] Børge G Nordestgaard,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.
[19] B. Nordestgaard,et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. , 2008, Circulation.
[20] J. Danesh,et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. , 2008, Archives of internal medicine.
[21] E. Brilakis,et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.
[22] Sangita Kulathinal,et al. MORGAM (an international pooling of cardiovascular cohorts). , 2004, International journal of epidemiology.
[23] Laura Antolini,et al. Inference on Correlated Discrimination Measures in Survival Analysis: A Nonparametric Approach , 2004 .
[24] A. Ariyo,et al. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. , 2003, The New England journal of medicine.
[25] Shah Ebrahim,et al. JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .
[26] J. Joven,et al. Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. , 2003, Clinical biochemistry.
[27] S. Lange,et al. Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.
[28] A. Wu,et al. Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly. The SENECA study. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[29] R. Collins,et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.
[30] G. Dagenais,et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. , 1998, Journal of the American College of Cardiology.
[31] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[32] P. Durrington,et al. Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. , 1990, Atherosclerosis.
[33] J. Loscalzo,et al. Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.
[34] G. Utermann,et al. The mysteries of lipoprotein(a). , 1989, Science.
[35] A. Hamsten,et al. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.
[36] Scanu Am. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. , 1988 .
[37] A. Scanu. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. , 1988, Archives of pathology & laboratory medicine.
[38] A. Gotto,et al. Human plasma lipoprotein [a]. Structural properties. , 1983, The Journal of biological chemistry.
[39] A. R. Jonckheere,et al. A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES , 1954 .